Respiratory Safety Evaluation in Mice and Inhibition of Adenoviral Amplification in Human Bronchial Endothelial Cells Using a Novel Type of Chlorine Dioxide Gas Reactor

Since the onset of the COVID-19 pandemic, there has been a growing demand for effective and safe disinfectants. A novel use of chlorine dioxide (ClO(2)) gas, which can satisfy such demand, has been reported. However, its efficacy and safety remain unclear. For the safe use of this gas, the stable release of specific concentrations is a must. A new type of ClO(2) generator called Dr.CLO(TM) has recently been introduced. This study aimed to investigate: (1) the effects of Dr.CLO(TM) on inhibiting adenoviral amplification on human bronchial epithelial (HBE) cells; and (2) the acute inhalation safety of using Dr.CLO(TM) in animal models. After infecting HBE cells with a recombinant adenovirus, the inhibitory power of Dr.CLO(TM) on the virus was expressed as IFU/mL in comparison with the control group. The safety of ClO(2) gas was indirectly predicted using mice by measuring single-dose inhalation toxicity in specially designed chambers. Dr.CLO(TM) was found to evaporate in a very constant concentration range at 0–0.011 ppm/m(3) for 42 days. In addition, 36–100% of adenoviral amplification was suppressed by Dr.CLO(TM), depending on the conditions. The LC(50) of ClO(2) gas to mice was approximately 68 ppm for males and 141 ppm for females. Histopathological evaluation showed that the lungs of female mice were more resistant to the toxicity from higher ClO(2) gas concentrations than those of male mice. Taken together, these results indicate that Dr.CLO(TM) can be used to provide a safe indoor environment due to its technology that maintains the stable concentration and release of ClO(2) gas, which could suppress viral amplification and may prevent viral infections.